Compass Pathways
Compass Pathways is developing COMP360 psilocybin treatment for treatment-resistant depression.
compasspathways.com ↗Why it's here
Raised about $150M gross in a January 2025 financing, followed by a further offering of about $150M at $8.00 per ADS in February 2026.
source: sec.gov- Focus
- Psychedelic medicine
- Founded
- 2016
- Latest round
- Public offering, about $150M, Feb 2026
- London office
- 33 Broadwick Street, London W1F 0DQ, Westminster W1F 0DQsource: sec.gov
- London presence
- HQsource: sec.gov
- Nearest station
- Piccadilly Circus, 397 m
Verified 7 Oct 2026. How we verify · Suggest a fix
Same building
2 more companies on the map list this office address.